Evidence map›Paper›PMID 36211984›Full record

ArticleVacunas

Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study.

Fazlollah Shokri, Saeed Rezapoor, Masoud Najafi, Mohsen Asadi, Mohammad Karimi Alavije, Moussa Abolhassani, Mohammad Hossein Moieneddin, Amir Muhammad Ashrafi, Narges Gholipour, Parisa Naderi and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vacunas. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. The effect of oseltamivir use in critically ill patients with COVID-19: A multicenter propensity score-matched study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 2 countries.

Fazlollah ShokriDepartment of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Saeed RezapoorDepartment of Radiology, Imam Khomeini Hospital, Amol, Iran.
Masoud NajafiMedical Technology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Mohsen AsadiDepartment of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Karimi AlavijeDepartment of Infectious Disease, Imam Reza Hospital, Amol, Iran.
Moussa AbolhassaniInv. Member, International Federation of Inventors' Associations-IFIA, Geneva, Switzerland.
Mohammad Hossein MoieneddinStudent Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran.
Amir Muhammad AshrafiStudent Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran.
Narges GholipourDepartment of Critical Care Nursing, School of Nursing and Midwifery (Nasibeh), Mazandaran University of Medical Sciences, Sari, Iran.
Parisa NaderiDepartment of Biology, Faculty of Cellular and Molecular Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran.
Jamshid Yazdani CharatiDepartment of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran.
Reza Alizadeh-NavaeiGastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran.
Majid SaeediDepartment of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Science, Sari, Iran.
Mohsen HeidaryCellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran.
Mostafa RostamnezhadDepartment of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Mazandaran University of Medical Sciences · IRImam Khomeini Hospital · IRImam Reza Hospital · IRIslamic Azad University Central Tehran Branch · IRKermanshah University of Medical Sciences · IRMashhad University of Medical Sciences · IRSabzevar University of Medical Sciences · IRShahid Beheshti University of Medical Sciences · IRTarbiat Modares University · IRThe Geneva Association · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Coronavirus disease 2019 (COVID-19) is the most critical issue in nowadays medicine. We aimed to evaluate the use and therapeutic outcomes of oseltamivir, an antiviral drug for patients with COVID-19. Materials and method: In an observational study conducted at Imam Khomeini Hospital in Amol, Iran, data for 544 patients with laboratory and CT scan result confirmed COVID-19 were retrospectively collected between February 24th and April 13th 2020. To compare the characteristics of patients based on gender, the chi-square test was used. Logistic regression was used to evaluate the effect of oseltamivir on the outcome of treatment. Logrank test were used to compare the length of hospital stay in people treated with oseltamivir and drugs other than oseltamivir. Results: Kaplan-Meier and logrank test showed no significant reduction in hospitalization time and survival rate following treatment with oseltamivir. However, a significant increase in lymphocytes count and reduction of C-reactive protein (CRP) level detected. Conclusion: Administration of oseltamivir for patients with COVID-19 didn't show any improvement in hospitalization duration and survival rate.

Indexed as

COVID-19HospitalizationOseltamivirSARS-CoV-2

Identifiers

PMID36211984
PMCPMC9531663
OpenAlexW4301394228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.